In Vivo Inhibitory Effect of Suberoylanilide Hydroxamic Acid Combined With Sorafenib on Human Hepatocellular Carcinoma Cells. Braz. J. Pharm. Sci. 2020, 56, e18254. https://doi.org/10.1590/s2175-97902019000318254.